The comprehensive assessment of intra-tumoral CCL5+ TAMs could strengthen our understanding of the infiltration characteristics of TILs and help tailor precise immunotherapy and targeted combination strategies for individual ccRCC patients. The gene discussed is CCL5; the disease is nonpapillary renal cell carcinoma.